Semaglutide vs tirzepatide: how they compare
Semaglutide and tirzepatide are both once-weekly injectable GLP-1 medications, but they work through different receptor pathways. This guide explains how they compare by mechanism and how a provider weighs the options.
If you have been reading about weight management medications, you have probably seen two names come up again and again: semaglutide and tirzepatide. They are often mentioned in the same breath, which can make it hard to tell what actually separates them. Both belong to a broader group of medications that act on gut hormone pathways, and both are used in once-weekly injectable forms in Medlly's weight line. This article walks through how they compare at the level of mechanism, in plain language, so you can have a more informed conversation with a provider.
How each one works
Semaglutide is a GLP-1 receptor agonist, which means it mimics a natural gut hormone called GLP-1 that helps signal fullness and influence how the body handles blood sugar. Tirzepatide acts on two receptor pathways at once, both GIP and GLP-1, which is why it is often described as a dual agonist. In simple terms, semaglutide targets one of these hormone systems while tirzepatide engages two. The practical meaning of that difference for any single person is something only a licensed provider can interpret in context.
What they share
Both medications are designed to be taken as a once-weekly injection in this category, and both work by acting on appetite and metabolic signaling rather than by adding stimulants or burning calories directly. They are typically started at a low dose and adjusted gradually under provider guidance. Both also carry possible side effects, which commonly include nausea and other digestive changes, and these should always be discussed with a provider before and during treatment.
Not the brand product
It is important to be clear that the semaglutide and tirzepatide offered through Medlly are compounded medications, and compounded medications are not FDA-approved. This means they have not been evaluated by the FDA for safety, effectiveness, or quality. They are also not the same as brand-name products such as Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound, which are separate, FDA-approved medications made by their manufacturers. Naming those brands here is only to help clarify what Medlly's products are not.
How a provider decides
There is no single right answer that applies to everyone, and these notes are general education rather than a recommendation or a diagnosis. A licensed provider reviews your health history, current medications, and goals to decide whether either option is clinically appropriate for you and which might fit better. A consultation is the first step in that process, and it does not guarantee that any prescription will be issued. The honest reality is that these medications are not suitable for everyone, and a provider may determine that neither is right for you.
Explore weight management
See if provider-guided care is right for you.
